Neurological Sciences

, Volume 31, Supplement 3, pp 321–323 | Cite as

Natalizumab efficacy on cognitive impairment in MS

Session III – Natalizumab: Update on New Clinical and Radiological Evidence

Abstract

We report follow-up data on the efficacy of natalizumab therapy on neuropsychological impairment on an italian MS group of 39 patients at 1 year and of 11 patients at 2 years. Results show a significant reduction in relapse rate, in the number of impaired neuropsychological tests as well as in several single executive function and reasoning tests scores at 1 year. Improvement persisted at 2 years, including also memory and speed processing tasks. These data support the efficacy of natalizumab therapy in all the clinical domains, including cognitive deterioration, in multiple sclerosis patients.

Keywords

Natalizumab Cognitive impairment Multiple sclerosis 

References

  1. 1.
    Rudick RA, Sandrock A (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4(4):571–580CrossRefPubMedGoogle Scholar
  2. 2.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910CrossRefPubMedGoogle Scholar
  3. 3.
    Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8(3):254–260CrossRefPubMedGoogle Scholar
  4. 4.
    Rudick RA, Miller D, Hass S et al (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62(4):335–346CrossRefPubMedGoogle Scholar
  5. 5.
    Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7(12):1139–1151CrossRefPubMedGoogle Scholar
  6. 6.
    Patti F (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15(1):2–8CrossRefPubMedGoogle Scholar
  7. 7.
    Mattioli F, Stampatori C, Capra R (2010) The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: a one-year follow-up study. Neurol Sci (submitted)Google Scholar
  8. 8.
    Gronwall DM (1977) Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 44(2):367–373PubMedGoogle Scholar
  9. 9.
    Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39:15–22CrossRefPubMedGoogle Scholar
  10. 10.
    Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di ricerca e produzione lessicale Taratura su soggetti normali. Archivio di Psicologia. Neurologia e Psichiatria 47(4):477–506Google Scholar
  11. 11.
    Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 8(Suppl):1–120Google Scholar
  12. 12.
    Rao SM, Cognitive Function Study Group, National Multiple Sclerosis Society (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society, New YorkGoogle Scholar
  13. 13.
    Meyers J, Meyers K (1995) Rey complex figure and recognition trial: professional manual. Psychological Assessment Resources, OdessaGoogle Scholar
  14. 14.
    Mattioli F, Stampatori C, Zanotti D, Parrinello G, Capra R (2009) Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis. J Neurol Sci 288(1):101–105Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • F. Mattioli
    • 1
  • C. Stampatori
    • 1
  • F. Bellomi
    • 1
  • R. Capra
    • 2
  1. 1.Neuropsychology UnitSpedali Civili of BresciaBresciaItaly
  2. 2.Multiple Sclerosis CenterSpedali Civili of BresciaBresciaItaly

Personalised recommendations